Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 489 Results

Page 44 of 49« First «...10 20 30...42 434445 46...»Last »

March 25, 2014

DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014

March 17, 2014

DBV Technologies Reports Full Year 2013 Financial Results and Provides VIPES Update

March 4, 2014

Presentation and Publication of Research at AAAAI Demonstrates EPITTM’s Ability to rebalance the Immune System and Induce a Disease-Modifying Effect

February 18, 2014

DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease

January 30, 2014

DBV Technologies Reports Full Year 2013 Topline Financial Results

December 17, 2013

DBV provides 2013 year-end summary and news flow guidance for 2014

December 13, 2013

Dr. Hugh Sampson presents Epicutaneous Immunotherapy for Food Allergy at the World Allergy Organization Conference

November 26, 2013

DBV Technologies Enters into Collaboration Agreement with BioNetAsia and University of Geneva on Whooping Cough Booster Vaccine

November 14, 2013

DBV Technologies announces the completion of a €29.9m private placement with a majority placed with US investors

October 24, 2013

NIH-sponsored Consortium of Food Allergy Research (CoFAR) starts a Phase II clinical study with DBV Technologies’ Viaskin^® Peanut in the treatment of peanut allergy

Page 44 of 49« First «...10 20 30...42 434445 46...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top